| Name | Title | Contact Details |
|---|---|---|
Bryan Garabrandt |
Chief Technologist | Profile |
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Mr. Gallagher is Senior Vice President & Chief Financial Officer at RRD International, LLC. Mr. Gallagher provides strategic, operational, and financial leadership to RRD. His primary responsibilities are planning, implementing, managing, and controlling all financial-related activities including the development of financial and operational strategies. Mr. Gallagher has over 20 years of finance experience in the biopharma industry with both multi-national corporations and commercial-stage public biotechnology companies. He has an extensive background in all areas of corporate controllership, including financial planning & analysis, cost control, management accounting, corporate administration, and systems implementation. He has supported all aspects of product development and commercialization, including the negotiation and execution of licensing and collaboration agreements with major pharma partners. Mr. Gallagher served previously as Vice President of Finance for Optimer Pharmaceuticals and, prior to that, as Senior Director of Finance and Corporate Controller for Adolor Corporation. He had a central role in the sale of both companies. Mr. Gallagher spent the first 10 years of his career with Therakos, Inc. (a Johnson & Johnson company) and Merck & Co., Inc. He received his BS in Finance from The Pennsylvania State University and is an active Certified Management Accountant (CMA).
National Stroke Association is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hendricks Regional Health is a non-profit, multi-specialty healthcare organization caring for communities in the Western and Central suburban area of Indianapolis since 1962, with a full-service hospital in Danville and medical buildings in Avon, Bainbridge, Brownsburg, Plainfield and Lizton. In December 2017, we will be opening our second hospital to serve the growing needs of the Brownsburg area.
Diagnostic Imaging, P.C is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.